Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Overweight 2 Melanoma 2 Skin Neoplasms 1 Metabolic Syndrome 1 Kidney Neoplasms 1 Inflammation 1 Glioma 1 Glioblastoma 1 Dyslipidemias 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 109 Magnetic Resonance Spectroscopy 52 Bevacizumab 52 Radiotherapy 44 Irinotecan 27 Blood Specimen Collection 19 Surgical Procedures, Operative 16 Radiation 15 Aminolevulinic Acid 15 Carboplatin 13 fluorodopa F 18 12 Nivolumab 12 Radiotherapy, Intensity-Modulated 11 Carmustine 11 Radiosurgery 10 Magnetic Resonance Imaging 10 pembrolizumab 9 Topotecan 9 Specimen Handling 9 Everolimus 9 Erlotinib Hydrochloride 9 Biopsy 9 poly ICLC 8 Surveys and Questionnaires 8 Standard of Care 8 Etoposide 8 Drug Therapy 8 Lomustine 7 Filgrastim 7 Cyclophosphamide 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioma × Naltrexone × Clear all

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡